Impact of HBV and HCV coinfection on CD4 cells among HIV-infected patients: a longitudinal retrospective study.
| Autor: | Silva CMD; Maringá State University, Maringá, Paraná, Brazil. claudinei@fag.edu.br., Peder LD; Maringá State University, Maringá, Paraná, Brazil. leydepeder@yahoo.com.br., Silva ES; State University Maringa, Maringá, Paraná, Brazil., Previdelli I; State University Maringa, Maringá, Paraná, Brazil. isoldeprevidelli@gmail.com., Pereira OCN; State University Maringa, Maringá, Paraná, Brazil. omarcnpereira@gmail.com., Teixeira JJV; State University Maringa, Maringá, Paraná, Brazil. jjvteixeira@gmail.com., Bertolini DA; State University Maringa, Maringá, Paraná, Brazil. dabertolini18@gmail.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of infection in developing countries [J Infect Dev Ctries] 2018 Nov 30; Vol. 12 (11), pp. 1009-1018. Date of Electronic Publication: 2018 Nov 30. |
| DOI: | 10.3855/jidc.10035 |
| Abstrakt: | Introduction: The impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection on CD4 cells in patients with human immunodeficiency virus (HIV) is unclear. We aimed to examine the impact of HBV and HCV coinfection on CD4 cell count and CD4/CD8 ratio in adults with HIV. Methodology: We conducted a longitudinal retrospective study in Brazil between January 1, 2002, and June 30, 2016, including 205 patients with HIV monoinfection, 37 with HIV-HBV coinfection, 35 with HIV-HCV coinfection, and 62 with HIV-HCV (48 HCV genotype 1 and 14 HCV genotype 3). Results: Median duration of follow-up was 2,327 (interquartile range: 1,159-3,319) days. An increased CD4 cell count and CD4/CD8 ratio over time was observed in all groups receiving combined antiretroviral therapy (cART). Patients with HIV-HBV or HIV-HCV coinfection and those with HIV monoinfection, showed comparable CD4 cell counts and CD4/CD8 ratios during pre-ART. There was also no statistically significant difference in CD4/CD8 ratio between HIV-HBV or HIV-HCV coinfection groups and the HIV monoinfection group during follow-up on cART. However, CD4 cell counts were significantly lower in HIV-HCV patients than in HIV monoinfection patients during follow-up on cART. HIV patients with HCV genotype 3 coinfection showed significantly lower CD4/CD8 ratio during follow-up on cART than those coinfected with HCV genotype 1 coinfection. No statistically significant effect of coinfection was observed on the efficacy of cART. Conclusions: HIV-infected patients are more likely to show better immunological responses to cART when they are not coinfected with HCV. Competing Interests: No Conflict of Interest is declared (Copyright (c) 2018 Claudinei Mesquita da Silva, Leyde Daiane de Peder, Isolde Previdelli, Omar Cleo Neves Pereira, Jorge Juarez Vieira Teixeira, Dennis Armando Bertolini.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|